Vertical Tabs


Measure of Ovarian Symptoms and Treatment (MOST) 
MOST is a validated instrument that was developed by the GCIG to measure the impact of palliative chemotherapy on cancer related to symptoms as well as on symptoms related to adverse effects of treatment reported by patients receiving chemotherapy for recurrent ovarian cancer.

Watermarked MOST questionnaires and scoring instructions are provided here.  Access to editable MOST questionnaires are available after registration using the link at the bottom of the page.

Registration to Access Editable MOST Questionnaires


GCIG Pathology
Clinical Q&A

Recent clinical questions posed to the group by GCIG members. Click the link to see full list of replies.



Submitted By

Clear Cell Carcinoma of the Cervix Michael Quinn
Laparoscopic BSO in Turner Syndrome Patient Philipp Harter
Grade 1 Immature Teratoma Michael Birrer
UTROSCT (Uterine Tumor Resembling Ovarian Sex Cord Tumor) Mansoor Raza Mirza
Grade 3 Mucinous Tumor Michael Quinn
Carcinosarcoma of the Ovary Amit Oza
Ewing Sarcoma of the ovary Philipp Harter
Sertoli-Leydig-tumor Andreas duBois
Adenocarcinoma of the Vulva Brigitte Miller
Endometriosis with adenocarcinoma Christian Marth
Alveolar soft tissue sarcoma Stefano Greggi
Endometrial high-grade stromal sarcoma David Gaffney
Small cell carcinoma of the cervix Michael Birrer
Small cell carcinoma of the ovary David Gaffney
Endocervical adenocarcinoma Andres Poveda
Recurrent Sertoli-Leydig tumor Michael Friedlander
Angiosarcoma of the ovary Ana Oakin
GTD Michael Quinn
Small cell carcinoma of the uterine cervix Bill Small